Pharming Group (NASDAQ:PHAR) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research note released on Thursday morning, Benzinga reports. They currently have a $37.00 target price on the stock.

Pharming Group Trading Up 5.7 %

Shares of PHAR stock opened at $8.49 on Thursday. The company’s 50-day moving average price is $7.79 and its 200-day moving average price is $8.87. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40. The stock has a market cap of $575.88 million, a price-to-earnings ratio of -53.06 and a beta of 0.14. Pharming Group has a twelve month low of $6.65 and a twelve month high of $13.40.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The company had revenue of $74.09 million during the quarter, compared to analyst estimates of $71.95 million. During the same period in the previous year, the company earned $0.02 EPS. As a group, equities analysts predict that Pharming Group will post -0.15 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.